Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Obesity Surgery

Volumn 26, Issue 5, 2016, Pages 1021-1028

  Shikora, Scott A ^a,b   Toouli, James ^c   Herrera, Miguel F ^d   Kulseng, Bård ^e   Brancatisano, Roy ^f   Kow, Lilian ^c   Pantoja, Juan P ^d   Johnsen, Gjermund ^e   Brancatisano, Anthony ^f   Tweden, Katherine S ^b   Knudson, Mark B ^b   Billingto, Charles J ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EnteroMedics Inc   (United States)

^c Flinders Private Hospital   (Australia)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f Institute of Weight Control   (Australia)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Obesity; Type 2 diabetes mellitus; VBLOC

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; METFORMIN; PIOGLITAZONE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIGESTIVE THERAPEUTIC DEVICE; ELECTRODE; ELECTROSTIMULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEARTBURN; HUMAN; LEAD BREAKAGE; LONG TERM CARE; MAESTRO RECHARGEABLE SYSTEM; MALE; MEAN ARTERIAL PRESSURE; MEDICAL DEVICE COMPLICATION; NAUSEA; NERVE BLOCK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VAGUS NERVE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

ADULT; AUTONOMIC NERVE BLOCK; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; VAGUS NERVE; WEIGHT LOSS;

EID: 84944711585     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1914-1     Document Type: Article

References (14)

1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102–38.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
3. Diabetes Prevention Program Research G, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.
4. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
5. Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA. 2014;312:915–22.
6. Shikora S, Toouli J, Herrera MF, et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. J Obes. 2013;2013:245683.
7. Camilleri M, Toouli J, Herrera MF, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery. 2008;143:723–31.
8. The seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC-7). Bethesda, National Institutes of Health (US); 2003.
9. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309:2240–9.
10. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.
11. Brethauer SA, Harris JL, Kroh M, et al. Laparoscopic gastric plication for treatment of severe obesity. Surg Obes Relat Dis. 2011;7:15–22.
12. de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23:1354–60.
13. Miras M, Serrano M, Duran C, et al. Early experience with customized, meal-triggered gastric electrical stimulation in obese patients. Obes Surg. 2015;25:174–9.
14. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:186–94.